Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. [electronic resource]
Producer: 20200611Description: 239-253 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols
- Female
- Humans
- Ipilimumab -- administration & dosage
- Lung Neoplasms -- drug therapy
- Male
- Mesothelioma -- drug therapy
- Mesothelioma, Malignant
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Nivolumab -- administration & dosage
- Pleural Neoplasms -- drug therapy
- Prospective Studies
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.